The United States Preventive Services Task Force (USPSTF) finalized its statement on the use of statins for primary prevention of cardiovascular disease (CVD) last week, polarizing the medical community like a partisan bill on the Senate floor.
The USPSTF based its recommendation on 23 clinical trials and three observational studies that assessed the head-to-head use of a statin with either placebo or no statin on CVD risk. True to brand, the task force erred on the side of caution and recommended a conservative approach.
Read more »
